Inari Medical (NARI)
(Delayed Data from NSDQ)
$57.98 USD
+3.18 (5.80%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $58.68 +0.70 (1.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.98 USD
+3.18 (5.80%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $58.68 +0.70 (1.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Zacks News
Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.
Strength Seen in Inari Medical, Inc. (NARI): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.
Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 20.83% and 6.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Alphatec (ATEC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
Inari Medical (NARI) Posts Positive Results of FLASH Registry
by Zacks Equity Research
Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.
Inari Medical, Inc. (NARI) Down 16.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 17.39% and 5.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Meets Q1 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0% and 5.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alphatec (ATEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 11.99% and 11.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment toward understanding the venous system. However, dependency on the wide adoption of products is a woe.
Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.
Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 25% and 4.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Inari Medical, Inc. (NARI): Can Its 6.2% Jump Turn into More Strength?
by Zacks Equity Research
Inari Medical, Inc. (NARI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Inari Medical, Inc. (NARI) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari Medical (NARI) Gains 12.5% Despite In-Line Q4 Earnings
by Zacks Equity Research
Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all of its growth drivers.
Inari Medical (NARI) Posts Solid Preliminary Q4, FY2021 Revenues
by Zacks Equity Research
Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.
New Strong Sell Stocks for November 10th
by Zacks Equity Research
AZN, GOLD, NARI, KOP, and TCEHY have been added to the Zacks Rank #5 (Strong Sell) List on November 10, 2021.